Study investigating the safety and efficacy of a new iodine formulation called DLQ03 in a wound-healing model in patients with atopic eczema

Prior treatment

• Ongoing use of prohibited atopic dermatitis treatments. Washout periods prior to baseline (first dose of the study drug) are as follows:

Other illness

• Any current and / or recurrent clinically significant skin condition which will interfere with the clinical findings of the study as assessed by the investigator.

• Male and female subjects with mild to moderate AD (IGA 2 or 3) 18 to 65 years of age, inclusive. The health status is verified by absence of evidence of any clinically significant active or uncontrolled chronic disease other than AD that potentially may influence the adherence to the study and/or assessments in the study, following a detailed medical history and a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, virology, and urinalysis.
• Diagnosed with AD according to the Hannifin criteria (Hannifin 1980
• Suitable target lesion defined as an eczema lesion of at least 0.5% BSA (excluding the face) at screening and baseline day 1 for part A and 2 suitable target lesions defined as two eczema lesions of at least 0.5% BSA (excluding the face) at screening and baseline day 1 for part B.
• Target lesion is cultured positive for S. aureus on two consecutive occasions during the screening period: